The stock of Agios Pharmaceuticals Incorporated (NASDAQ:AGIO) registered a decrease of 4.33% in short interest. AGIO’s total short interest was 6.36M shares in September as published by FINRA. Its down 4.33% from 6.65 million shares, reported previously. With 563,700 shares average volume, it will take short sellers 11 days to cover their AGIO’s short positions. The short interest to Agios Pharmaceuticals Incorporated’s float is 25.89%. About 435,837 shares traded hands. Agios Pharmaceuticals Inc (NASDAQ:AGIO) has risen 27.54% since February 8, 2016 and is uptrending. It has outperformed by 11.05% the S&P500.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $1.86 billion. The Firm is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders , which are a subset of orphan genetic metabolic diseases. It currently has negative earnings. The Company’s cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
The institutional sentiment increased to 1.39 in Q2 2016. Its up 0.03, from 1.36 in 2016Q1. The ratio increased, as 22 funds sold all Agios Pharmaceuticals Inc shares owned while 37 reduced positions. 18 funds bought stakes while 64 increased positions. They now own 35.06 million shares or 11.59% more from 31.42 million shares in 2016Q1.
Flagship Ventures 2007 General Partner Llc holds 75.24% of its portfolio in Agios Pharmaceuticals Inc for 1.93 million shares. University Of Texas Investment Managment Co owns 40,000 shares or 4.87% of their US portfolio. Moreover, Bb Biotech Ag has 3.91% invested in the company for 2.36 million shares. The Massachusetts-based Opaleye Management Inc. has invested 2.54% in the stock. Alpinvest Partners B.V., a Netherlands-based fund reported 30,000 shares.
Out of 10 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 5 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 50% are positive. Agios Pharmaceuticals has been the topic of 16 analyst reports since October 19, 2015 according to StockzIntelligence Inc. BTIG Research initiated the stock on August 19 with “Neutral” rating.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.